Founded in San Diego, California, Acadia Pharmaceuticals is a biopharmaceutical company dedicated to the discovery, development, and commercialization of small molecule drugs aimed at treating central nervous system (CNS) disorders. The company's core mission is to advance breakthroughs in neuroscience to elevate life quality for patients. Acadia’s product portfolio includes the first and only approved therapies for hallucinations and delusions associated with Parkinson’s disease psychosis and Rett syndrome. Their market focus encompasses treatments for Parkinson’s disease, schizophrenia, neuropathic pain, and glaucoma.
Acadia Pharmaceuticals has made significant strides in the biopharmaceutical industry, backed by notable investors and a team of experienced professionals in neuroscience and drug development. The company has achieved key milestones such as pioneering groundbreaking therapies for CNS disorders, which have had a profound impact on patient care. Acadia's innovative approach and commitment to addressing unmet medical needs have solidified its reputation as a leader in the field of CNS disorder treatments.
